Pharmacological treatment of children with gastro-oesophageal reflux

Publisher:
Cochrane Collaboration
Publication Type:
Journal Article
Citation:
Cochrane Database of Systematic Reviews, 2014, (11)
Issue Date:
2014-11-24
Full metadata record
Files in This Item:
Filename Description Size
Tighe_et_al-2014-The_Cochrane_Library.pdfPublished Version1.05 MB
Adobe PDF
Gastro-oesophageal reflux (GOR) is a common disorder, characterised by regurgitation of gastric contents into the oesophagus. GOR is a very common presentation in infancy in both primar y and secondary care settings. GO R can affect approximately 50% of infants younger than three months old. The natural history of GOR in infancy is generally that of a functional, self-limiting condition that improves with age; < 5% of children with vomiting or regurgitation continue to have symptoms after infancy. Older children and children with co-existing medical conditions can have a more protracted course. The de finition of gastro-oesophageal reflux disease (GORD) and its precise distinction from GOR are de bated, but consensus guidelines from the North American Society of Gastroenterology, Hepatology and Nutrition define GORD as ’troublesome symptoms or complications of GOR.’ Objectives This Cochrane review aims to provide a robust analysis of currently available pharmacological interventions used to treat children with GOR by assessing all outcomes indicating benefit or harm.
Please use this identifier to cite or link to this item: